Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia

Author:

Abdullaev Skokhrukh P.1ORCID,Shatokhin Maksim N.12,Tuchkova Svetlana N.1,Abdullaev Sherzod P.2,Teodorovich Oleg V.12,Loran Oleg B.1,Sychev Dmitry A.1

Affiliation:

1. Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia

2. Central Clinical Hospital of “Russian Railways Medicine” , Moscow , Russia

Abstract

Abstract Objectives Tamsulosin is a first-line drug for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Despite its high ratings for efficacy and safety, these parameters may vary due to genetic polymorphisms of CYP2D6 enzyme, which is involved in the metabolism of the drug. This variability may have great impact on the therapy of LUTS associated with BPH and may require an individualized approach to drug selection. The aim of the study was to assess the impact of genetic polymorphisms in CYP2D6 on the efficacy and safety of tamsulosin therapy in patients with LUTS associated with BPH. Methods The study included 106 patients with LUTS/BPH (N40 according to ICD-10). All patients received monotherapy with tamsulosin 0.4 mg/day for at least 8 weeks. Depending on the severity of symptoms, all patients were divided into 2 groups based on the IPSS score: the first group of patients had moderate symptoms (n=57), and the second group of patients had severe symptoms (n=49). The results of treatment were assessed using the IPSS questionnaire with determination of quality of life (QoL), transrectal ultrasound of the prostate with determination of prostate volume and postvoid residual urine volume, and uroflowmetry. The carriage of allelic variants of CYP2D6 (*3, *4, *9, *10, and *41) were determined by polymerase chain reaction in all patients. Results In patients with moderate symptoms who was classified as «intermediate» metabolizers by CYP2D6, a statistically significant greater reduction in symptoms according to the overall IPSS scale at 8 weeks (p=0.046) and the obstructive symptom subscale starting from 4 weeks of treatment (p<0.05) was shown. Allelic variants of the CYP2D6 gene did not affect the frequency of adverse reactions to tamsulosin. Conclusions The results of the study show that in patients with moderate LUTS associated with BPH who are «intermediate» metabolizers by CYP2D6, there is a better therapeutic effect of tamsulosin.

Publisher

Walter de Gruyter GmbH

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Reference24 articles.

1. Lokeshwar, SD, Harper, BT, Webb, E, Jordan, A, Dykes, TA, Neal, DE, et al.. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019;8:529–39. https://doi.org/10.21037/tau.2019.10.01.

2. Parsons, JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010;5:212–8. https://doi.org/10.1007/s11884-010-0067-2.

3. Cornu, JN, Gacci, M, Hashim, H, Herrmann, TR, Malde, S, Netsch, C, et al.. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023 Arnhem, The Netherlands: EAU Guidelines Office. ISBN 978-94-92671-19-6.

4. Michel, MC, Kenny, B, Schwinn, DA. Classification of alpha 1-adrenoceptor subtypes. Naunyn-Schmiedeb Arch Pharmacol 1995;352:1–10. https://doi.org/10.1007/bf00169183.

5. Rasner, PI, Pushkar, DI. Lechenie simptomov nizhnikh mochevykh putei u patsientov s dobrokachestvennoi giperplaziei predstatel’noi zhelezy: sovremennye mezhdunarodnye standarty. Sprav Poliklin Vracha 2015;10:20–6.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Ancestromics;Drug Metabolism and Personalized Therapy;2023-12-07

2. Ancestromics;Drug Metabolism and Personalized Therapy;2023-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3